Advertisement

The Main Events in the History of Diabetes Mellitus

  • Rachel Goldman
  • Jacek Zajac
  • Anil Shrestha
  • Parini Patel
  • Leonid PoretskyEmail author
Reference work entry

Abstract

A medical condition producing excessive thirst, continuous urination, and severe weight loss has interested medical authors for over three millennia. Unfortunately, until the early part of the twentieth century the prognosis for a patient with this condition was no better than it was over 3000 years ago. Since the ancient physicians described almost exclusively cases of what is known today as type 1 diabetes mellitus, the outcome was invariably fatal.

Keywords

Diabetes timeline Major Diabetes Clinical trials Discovery of Insulin 

References

  1. 1.
    Papaspyros NS. The history of diabetes. In: Verlag GT, editor. The history of diabetes mellitus. Stuttgart: Thieme; 1964. p. 4.Google Scholar
  2. 2.
    http://www.crystalinks.com/egyptmedicine.html – ancient Egyptian medicine, Ebers papyrus.
  3. 3.
    Medvei VC. The Greco – Roman period. In: Medvei VC, editor. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest times to the present day. New York: Parthenon Publishing; 1993. p. 34–7.Google Scholar
  4. 4.
    Southgate TM. De medicina. JAMA. 1999;10:921.Google Scholar
  5. 5.
    Sanders LJ. From Thebes to Toronto and the 21st century: an incredible journey. Diabetes Spect. 2002;15:56–60.CrossRefGoogle Scholar
  6. 6.
    Medvei VC. Mediaeval scene. In: Medvei VC, editor. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest times to the present day. New York: Parthenon Publishing; 1993. p. 46–9.Google Scholar
  7. 7.
    Medvei VC. The 16th century and the renaissance. In: Medvei VC, editor. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest times to the present day. New York: Parthenon Publishing; 1993. p. 55–6.Google Scholar
  8. 8.
    Medvei VC. The 18th century and the beginning of the 19th century. In: Medvei VC, editor. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest Times to the present day. New York: Parthenon Publishing; 1993. p. 97.Google Scholar
  9. 9.
    www.uic.edu – Claude Bernard.
  10. 10.
    www.britannica.com – Claude Bernard.
  11. 11.
    Medvei VC. Story of insulin. In: Medvei VC, editor. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest times to the present day. New York: Parthenon Publishing; 1993. p. 249–51.Google Scholar
  12. 12.
    Schullian DM. John Rollo’s patient. J Hist Med. 1965;2:163–4.Google Scholar
  13. 13.
    Bliss M. A long prelude. In: Bliss M, editor. The discovery of insulin. Chicago: The University of Chicago Press; 1982. p. 33–9.Google Scholar
  14. 14.
    Minkowski O. Introduction and translation by R. Levine. Historical development of the theory of pancreatic diabetes. Diabetes. 1989;38:1–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Medvei VC. The birth of endocrinology. In: Medvei VC, editor. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest times to the present day. New York: Parthenon Publishing; 1993. p. 151.Google Scholar
  16. 16.
    Bliss M. Banting’s idea. In: Bliss M, editor. The discovery of insulin. Chicago: University of Chicago Press; 2007. p. 45–58.Google Scholar
  17. 17.
    Bliss M. A mysterious something. In: Bliss M, editor. The discovery of insulin. Chicago: University of Chicago Press; 2007. p. 84–103.Google Scholar
  18. 18.
    Bliss M. Triumph. In: Bliss M, editor. The discovery of insulin. Chicago: University of Chicago Press; 1982. p. 104–28.CrossRefGoogle Scholar
  19. 19.
    MacCracken J. From ants to analogues. Puzzles and promises in diabetes management. Postgrad Med. 1997;4:138–50.CrossRefGoogle Scholar
  20. 20.
    Pratt P. History of insulin. Hutchinson family encyclopedia. Online edition. Oxford: Helicon Publishing; 2000.Google Scholar
  21. 21.
    Born DM. The journey and the dream: a history of the American Diabetes Association. Alexandria: American Diabetes Association; 1990. p. 1–14.Google Scholar
  22. 22.
    www.nobel.se – August Krogh.
  23. 23.
    Medvei VC. Present trends and outlook for the future – part III. In: Medvei VC, editor. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest times to the present day. New York: Parthenon Publishing; 1993. p. 380–3.Google Scholar
  24. 24.
  25. 25.
    Segre GV, Brown EN. Measurement of hormones. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors. Williams textbook of endocrinology. 9th ed. Philadelphia: WB Saunders; 1998. p. 44–5.Google Scholar
  26. 26.
    Medvei VC. Chronological tables. In: Medvei VC, editor. The history of clinical endocrinology: a comprehensive account of endocrinology from earliest times to the present day. New York: Parthenon Publishing; 1993. p. 495.Google Scholar
  27. 27.
    www.gene.com – press release 6 Sept 1978.
  28. 28.
    Galloway J, DeShazo R. Insulin chemistry and pharmacology: insulin allergy, resistance, and lipodystrophy. In: Rifkin H, Porte Jr D, editors. Diabetes mellitus. Theory and practice. 4th ed. New York: Elsevier; 1990. p. 498.Google Scholar
  29. 29.
  30. 30.
  31. 31.
    Blevins TC, et al. Statement by the American Association of Clinical Endocrinologists Consensus panel on continuous glucose monitoring. Endocr Pract. 2010;16(5):730–45.CrossRefPubMedGoogle Scholar
  32. 32.
    Holmquist WR, Schroeder WA. A new N-terminal blocking group involving a Schiff base in hemoglobin A1c. Biochemistry. 1966;5:2489–503.CrossRefPubMedGoogle Scholar
  33. 33.
    Bookchin RM, Gallop PM. Structure of hemoglobin A1c: nature of the N-terminal β chain blocking group. Biochem Biophys Res Commun. 1968;32:86–93.CrossRefPubMedGoogle Scholar
  34. 34.
    Samuel R. An abnormal hemoglobin in red cells of diabetics. Clin Chim Acta. 1968;22:296–8.CrossRefGoogle Scholar
  35. 35.
    Rahbar S, Blumenfeld O, Ranney HM. Studies of an unusual hemoglobin in patients with diabetes mellitus. Biochem Biophys Res Commun. 1969;36:838–43.CrossRefPubMedGoogle Scholar
  36. 36.
    Tattersall RB, Pyke DA, Ranney HM, Bruckheimer SM. Hemoglobin components in diabetes mellitus: studies in identical twins. N Engl J Med. 1975;293:1171–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cermani A. Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. N Engl J Med. 1976;295:417–20.CrossRefPubMedGoogle Scholar
  38. 38.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefGoogle Scholar
  39. 39.
    The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381–9.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–53.CrossRefGoogle Scholar
  41. 41.
    UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRefGoogle Scholar
  42. 42.
    UK Prospective Diabetes Study Group. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.CrossRefGoogle Scholar
  43. 43.
    UK Prospective Diabetes Study Group. Effects of intensive blood-glucose control with metformin on complications in overweight patients with type 2 Diabetes (UKPDS 34). Lancet. 1998;325:854–65.Google Scholar
  44. 44.
    Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. NIH: National Heart, Lung, and Blood. Updated March 14, 2010. https://www.nhlbi.nih.gov/health-pro/resources/heart/accord-trial. Accessed 26 Sept 2015.
  45. 45.
    The Look AHEAD Research Group. The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity. 2006;14:737–52.CrossRefPubMedCentralGoogle Scholar
  46. 46.
    Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes: the Look AHEAD Research Group. N Engl J Med. 2013. doi: 10.1056/NEJMoa1212914.Google Scholar
  47. 47.
    Gruessner RWG, Sutherland D, Kandaswamy R, et al. Lessons learned from >500 pancreas transplants alone at a single institution. Am J Transplant. 2007;7:249.CrossRefGoogle Scholar
  48. 48.
    Lacy PE, Kostianovsky M. Methods for the isolation of intact islets of Langerhans from rat pancreas. Diabetes. 1967;16:35–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Wahoff DC, Papalois BE, Najarian JS, et al. Autologous islet cell transplant to prevent diabetes after pancreatic resection. Ann Surg. 1995;222:562–79.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Shapiro JAM, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060–8.CrossRefPubMedGoogle Scholar
  52. 52.
    Matsumoto S. Clinical allogeneic and autologous islet cell transplantation: update. Diabetes Metab J. 2011;35(3):199–206. doi:10.4093/dmj.2011.35.3.199.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Artificial Pancreas Project Research: Artificial Pancreas Project Plan. Juvenile Diabetes Research Foundation. JDRF 2015. http://jdrf.org/research/treat/artificial-pancreas-project/. Accessed 23 Aug 2015.
  54. 54.
    Clinical Studies and the Development of the Artificial Pancreas. U.S. Food and Drug Administration. U.S. Department of Health and Human Sevices. 2014. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/HomeHealthandConsumer/ConsumerProducts/ArtificialPancreas/ucm259568.htm. Accessed 23 Aug 2015
  55. 55.
    Russell SJ, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313–25. doi: 10.1056/NEJMoa1314474.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Overweight and obesity statistics. National Institute of Diabetes and Digestive and Kidney Diseases. U.S. Department of Health and Human Services. Updated Oct 2012. http://www.niddk.nih.gov/health-information/health-statistics/Pages/overweight-obesity-statistics.aspx. Accessed 26 Sept 2015.
  57. 57.
    Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a diabetes care editors’ expert forum. Diabetes Care. 2015;38:1567–82. doi:10.2337/dc15-1081.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Morbidity and Mortality Weekly Report. Center of diabetes control and prevention. MMWR. 2004;53:80–2.Google Scholar
  59. 59.
    Manson JE, Rimm EB, Stampfer MJ, et al. A prospective study of physical activity and incidence of non insulin-dependent diabetes mellitus in women. Lancet. 1991;338:774–7.CrossRefPubMedGoogle Scholar
  60. 60.
    U.S. Department of Health and Human Services. Healthy people 2000: summary report. Washington, DC: U.S. Department of Health and Human Services (DHHS Publ. PHSSs 91–50213); 1992. p. 6–8, 55, 91–2.Google Scholar
  61. 61.
    Tuomilehto J, Lindstrom J, Eriksson JG, Finnish Diabetes Prevention Study Group, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.CrossRefPubMedGoogle Scholar
  62. 62.
    Pan XR, Li GW, Wang JX, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.CrossRefPubMedGoogle Scholar
  63. 63.
    Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325:147–52.CrossRefPubMedGoogle Scholar
  64. 64.
    www.niddk.nih.gov – results of Diabetes Prevention Program, Diabetes Prevention Trial.
  65. 65.
    Diabetes Prevention Trial – Type 1 Diabetes Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med. 2002;346:1685–91.CrossRefGoogle Scholar
  66. 66.
    Diabetes Prevention Trial – Type 1 Diabetes Group. Effects of oral insulin in relatives of patients with type 1 diabetes. Diabetes Care. 2005;28:1068–76.CrossRefGoogle Scholar
  67. 67.
    Fowler, G. Dr. Ora M. Rosen, 55, scientist: studied the development of cells. The New York Times. 1 June 1990.Google Scholar
  68. 68.
    Rosen OM. After insulin binds. Science. 1987;237:1452–8. doi:10.1126/science.2442814.CrossRefPubMedGoogle Scholar
  69. 69.
    Scott LJ, Mohlke KL, Bonnycastle LL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341–5.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331–6.CrossRefPubMedGoogle Scholar
  71. 71.
    Zeggini E, Weedon MN, Lindgren CM, McCarthy MI, Hattersley AT. Replications of genome wide association signals in UIC sample reval risk loci for type Z diabetes. The Welcome Trust Case Control Consortium (WTCCC), et al. Science. 2007;316:1336–41.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Rachel Goldman
    • 1
  • Jacek Zajac
    • 2
  • Anil Shrestha
    • 2
  • Parini Patel
    • 2
  • Leonid Poretsky
    • 4
    • 3
    Email author
  1. 1.Division of Endocrinology, Diabetes and MetabolismLenox Hill Hospital, Hofstra Northwell School of Medicine, Northwell HealthNew YorkUSA
  2. 2.Division of Endocrinology and MetabolismBeth Israel Medical Center, Albert Einstein College of MedicineNew YorkUSA
  3. 3.Division of Endocrinology, Diabetes and Metabolism, Gerald J. Friedman Diabetes InstituteLenox Hill Hospital, Hofstra Northwell School of Medicine, Northwell HealthNew YorkUSA
  4. 4.Division of Endocrinology and MetabolismMount Sinai Beth Israel, Icahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations